Vedolizumab-4006

Open-label, Phase 4 study to evaluate the efficacy and safety of triple combination therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in early treatment of subjects with Crohn’s Disease stratified at higher risk for developing complications.

Sponsor: Takeda Development Center Americas, Inc.

Principal Investigator: Dr. William Holderman

We are looking for additional patients to participate in this study:

  • Biologic naive Crohn’s Disease patients diagnosed within the last 24 months
  • 18 to 65 years of age
  • High risk for developing complications